KR20120091258A - 파클리탁셀/스테로이드 복합체 - Google Patents

파클리탁셀/스테로이드 복합체 Download PDF

Info

Publication number
KR20120091258A
KR20120091258A KR1020127013922A KR20127013922A KR20120091258A KR 20120091258 A KR20120091258 A KR 20120091258A KR 1020127013922 A KR1020127013922 A KR 1020127013922A KR 20127013922 A KR20127013922 A KR 20127013922A KR 20120091258 A KR20120091258 A KR 20120091258A
Authority
KR
South Korea
Prior art keywords
paclitaxel
steroid
complex
cholesterol
submicron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127013922A
Other languages
English (en)
Korean (ko)
Inventor
윌링 리우
수에준 시아
루이팡 구오
펭시아오 장
퀴핑 조우
레？ 왕
두지아 진
Original Assignee
인스티투트 오브 마타리아 메디카, 차이니즈 아카데미 오브 메디칼 사이언스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인스티투트 오브 마타리아 메디카, 차이니즈 아카데미 오브 메디칼 사이언스 filed Critical 인스티투트 오브 마타리아 메디카, 차이니즈 아카데미 오브 메디칼 사이언스
Publication of KR20120091258A publication Critical patent/KR20120091258A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Epoxy Compounds (AREA)
KR1020127013922A 2009-10-29 2010-10-28 파클리탁셀/스테로이드 복합체 Ceased KR20120091258A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200910236960.7A CN102048725B (zh) 2009-10-29 2009-10-29 紫杉醇胆固醇复合物
CN200910236960.7 2009-10-29

Publications (1)

Publication Number Publication Date
KR20120091258A true KR20120091258A (ko) 2012-08-17

Family

ID=43921347

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127013922A Ceased KR20120091258A (ko) 2009-10-29 2010-10-28 파클리탁셀/스테로이드 복합체

Country Status (9)

Country Link
US (1) US20130150335A1 (https=)
EP (1) EP2494956A4 (https=)
JP (1) JP6158513B2 (https=)
KR (1) KR20120091258A (https=)
CN (2) CN102048725B (https=)
AU (1) AU2010312017B2 (https=)
BR (1) BR112012010149A2 (https=)
CA (1) CA2779316C (https=)
WO (1) WO2011050735A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220136909A (ko) * 2021-04-01 2022-10-11 에스엔제이 파마 인크 생활성물질의 경구용 나노입자 및 이의 제조방법

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102048688B (zh) * 2009-10-29 2014-03-05 中国医学科学院药物研究所 以胆固醇复合物为中间载体的紫杉醇亚微乳
EP2679225A1 (de) * 2012-06-26 2014-01-01 Universitätsklinikum Freiburg Pharmazeutische Zusammensetzung mit synergistischer Wirkung von direkten Katalaseinhibitoren und zur Katalasezerstörung führenden Modulatoren des NO-Stoffwechsels oder der extrazellulären Superoxidanionenproduktion
US11273105B2 (en) * 2017-06-16 2022-03-15 Sorse Technology Corporation Method for preparing solid forms of plant extract
CN108272747B (zh) * 2018-03-16 2020-02-18 武汉百纳礼康生物制药有限公司 一种非那雄胺溶致液晶凝胶制剂前体及其制备方法
KR20210078505A (ko) 2018-10-16 2021-06-28 유에스 나노 푸드 앤 드럭 인코포레이티드 종양내 주사 제형
WO2021211294A1 (en) 2020-04-13 2021-10-21 US Nano Food & Drug INC Basic chemotherapeutic intratumour injection formulation
CN115177589B (zh) * 2021-04-07 2024-02-06 中国医学科学院药物研究所 一种紫杉醇脑靶向脂质体和其制备方法及应用
CN115463110B (zh) * 2021-06-10 2023-12-15 中国医学科学院药物研究所 一种胆酸修饰的口服紫杉醇纳米粒、其制备方法及应用
CN115737654B (zh) * 2021-09-03 2025-11-21 成都瑞沐生物医药科技有限公司 一种滴眼给药预防和/或治疗白内障的眼用制剂
CN116196283A (zh) * 2021-11-30 2023-06-02 深圳玖星制药有限公司 一种注射用紫杉烷类药物脂质体冻干粉剂的制备方法及原料组方
CN117482052A (zh) * 2023-11-29 2024-02-02 中国药科大学 一种口服紫杉醇三元递药系统及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
US5827533A (en) * 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
CN1116875C (zh) * 2000-10-19 2003-08-06 南京振中生物工程有限公司 紫杉醇脂质组合物及其制备方法
US20090110739A1 (en) * 2007-05-15 2009-04-30 University Of North Texas Health Science Center At Forth Worth Targeted cancer chemotherapy using synthetic nanoparticles
CN101396343B (zh) * 2007-09-26 2011-12-07 中国医学科学院药物研究所 以脂质复合物为中间载体的紫杉醇亚微乳
CN102048688B (zh) * 2009-10-29 2014-03-05 中国医学科学院药物研究所 以胆固醇复合物为中间载体的紫杉醇亚微乳

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220136909A (ko) * 2021-04-01 2022-10-11 에스엔제이 파마 인크 생활성물질의 경구용 나노입자 및 이의 제조방법

Also Published As

Publication number Publication date
EP2494956A9 (en) 2013-04-17
CN102811706A (zh) 2012-12-05
CN102811706B (zh) 2015-05-06
AU2010312017B2 (en) 2014-07-17
JP6158513B2 (ja) 2017-07-12
CN102048725A (zh) 2011-05-11
US20130150335A1 (en) 2013-06-13
EP2494956A1 (en) 2012-09-05
JP2013509360A (ja) 2013-03-14
WO2011050735A1 (zh) 2011-05-05
CA2779316C (en) 2016-05-03
EP2494956A4 (en) 2013-10-23
HK1179513A1 (zh) 2013-10-04
BR112012010149A2 (pt) 2018-03-20
CN102048725B (zh) 2014-07-16
CA2779316A1 (en) 2011-05-05
AU2010312017A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
KR20120091258A (ko) 파클리탁셀/스테로이드 복합체
Jing et al. A novel polyethylene glycol mediated lipid nanoemulsion as drug delivery carrier for paclitaxel
CN104224711B (zh) 以类固醇复合物为中间载体的紫杉醇亚微乳
Man et al. Improved oral bioavailability of myricitrin by liquid self-microemulsifying drug delivery systems
WO2022160970A1 (zh) 一种不含乙醇的难溶性药物浓缩液以及由其制备的胶束溶液
Rawat Formulation, optimization and characterization of ellagic acid phyto-vesicular system for bioavailability enhancement
CN111643451B (zh) 一种注射用和厚朴酚自乳化微乳制剂及其制备方法
CN103690482B (zh) 以磷脂复合物为中间体的甘草酸自乳化制剂用浓缩液及制备方法
JPH02262514A (ja) 細胞親和性の不均質分子脂質（ｃｈｍｌ）およびその製造方法
CN116509819A (zh) 一种双载药重组高密度脂蛋白纳米粒及其制备方法和应用
CN115252551A (zh) 一种紫杉醇注射用微乳、冻干粉及其制备方法
CN102920657B (zh) 16-妊娠双烯醇酮亚微乳注射剂及其制备方法
CN110721155B (zh) 一种长效载药脂肪乳制剂及其制备方法
CN102451157B (zh) 以类固醇复合物为中间载体的多西紫杉烷亚微乳
Stadnichenko et al. Standardization of extrusion parameters during liposomal oxaliplatin creation
HK1179513B (en) Paclitaxel/steroidal complex
HK1175707B (en) Submicro emulsion of paclitaxel using steroid complex as intermediate carrier
CN112168785A (zh) 熊果酸脂质体制剂及其制备方法和用途

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20120529

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130927

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140722

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130927

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20141021

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20140722

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2014101006469

Request date: 20141021

J301 Trial decision

Free format text: TRIAL NUMBER: 2014101006469; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20141021

Effective date: 20160823

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20160824

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20141021

Decision date: 20160823

Appeal identifier: 2014101006469

J2X1 Appeal (before the patent court)

Free format text: TRIAL NUMBER: 2016201007909; APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

Patent event date: 20160824

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event code: PJ20011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2016201007909

Request date: 20161024

J302 Written judgement (patent court)

Free format text: TRIAL NUMBER: 2016201007909; JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20161024

Effective date: 20170317

PJ1302 Judgment (patent court)

Patent event date: 20170320

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20161024

Decision date: 20170317

Appeal identifier: 2016201007909

Appeal kind category: Appeal against decision to decline refusal